结直肠癌的治疗真实世界研究进展

张翔宇; 张帅; 赖浩; 冯雁; 林源

doi:10.12354/j.issn.1000-8179.2021.20201631

结直肠癌的治疗真实世界研究进展

doi: 10.12354/j.issn.1000-8179.2021.20201631

广西医科大学附属肿瘤医院胃肠外科（南宁市530021）

基金项目: 本文课题受广西重点研发项目（编号：AB16380202，AB18221086）资助

详细信息

作者简介:
张翔宇：专业方向为胃肠道肿瘤的外科治疗和临床预后预测体系研究

通讯作者:
林源　doctoryuanlin@sina.cn

计量
- 文章访问数: 254
- HTML全文浏览量: 36
- PDF下载量: 53
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-30
- 录用日期: 2021-11-29

Research progress of real world studies on colorectal cancer treatment

Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China

Funds: This work was supported by the Guangxi Science and Technology Department Science and Technology Development Key Project (No. AB16380202, No. AB 18221086)

More Information

Corresponding author: Yuan Lin; E-mail: doctoryuanlin@sina.cn

摘要

摘要: 近年来，在医药卫生领域，利用真实世界数据生成真实世界证据的研究方法在药品研发、审批、适应证拓展等领域取得广泛的关注和认可，开展真实可信、高质量的真实世界研究证据（real world evidence，RWE），已成为循证医学的一个重要发展方向。本文介绍了近年来国内外关于结直肠癌真实世界研究的现状，将真实世界研究（real world research/study，RWS）与相应的随机对照研究（randomized controlled trial，RCT）的meta分析结果进行对比和评价，以阐述RWS的特征、研究方法、相对于传统RCT研究的优势，并归纳其在肠癌领域的应用现状。在此基础上，对RWS在结直肠癌临床研究中的价值和前景进行总结，为后续研究提供新的思路。
- 真实世界研究 /
- 结直肠癌 /
- 随机对照研究
Abstract: In recent years, in the medical and health field, the research method of generating real world evidence (RWE) using real-world data has gained increasing attention and recognition in the areas of drug research and development, approval, and expansion of indications. In addition, it has become an important development direction of evidence-based medicine to discover authentic and high-quality RWE. In this review, recent articles on real world research/study (RWS) of colorectal cancer at home and abroad were introduced. Moreover, the results of the meta-analysis of RWS and its corresponding randomized controlled trials (RCT) were compared and evaluated to elaborate on the characteristics, research methods, and advantages of RWS compared with traditional studies, and the condition of RWS application in the field of colorectal cancer was summarized. On this basis, the value and prospects of RWS in clinical research on colorectal cancer were summarized, providing new ideas for researchers in the future.
- real world research/study (RWS) /
- colorectal cancer /
- randomized controlled trial (RCT)

HTML全文

参考文献(29)

[1]	田磊,岳彩宾,管欣,等.真实世界研究与随机对照试验在临床实践及卫生决策中应用的比较[J].中国医院药学杂志,2019,39(3):274-277.
[2]	曹越,尹庆锋,曾宪涛.真实世界研究概述[J].武警医学,2017,28(4):400-403. doi: 10.3969/j.issn.1004-3594.2017.04.024
[3]	刘晓清,孙晓川.真实世界证据[J].协和医学杂志,2017,8(Z2):305-310.
[4]	李敏,时景璞,于慧会.真实世界研究与随机对照试验、单病例随机对照试验在临床治疗性研究中的关系比较[J].中华流行病学杂志,2012,33(3):342-345. doi: 10.3760/cma.j.issn.0254-6450.2012.03.021
[5]	黄卓山,罗艳婷,刘金来.真实世界研究的方法与实践[J].循证医学,2014,14(6):364-368.
[6]	Grapow MT, Wattenwyl RV, Guller U, et al. Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines[J]. J Thorac Cardiovasc Surg, 2006, 132:5-7. doi: 10.1016/j.jtcvs.2006.03.035
[7]	Feinberg BA, Gajra A, Zettler ME, et al. Use of real-world evidence to support FDA approval of oncology drugs[J]. Value Health, 2020, 23(10):1358-1365. doi: 10.1016/j.jval.2020.06.006
[8]	李昱佳,陈垂雄,黄丽红,等.不同领域现实世界临床研究证据转化的应用策略[J].中国临床医学,2021,28(5):744-750. doi: 10.12025/j.issn.1008-6358.2021.20212080
[9]	Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23):2335-2342. doi: 10.1056/NEJMoa032691
[10]	Jang HJ, Kim BJ, Kim JH, et al. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomizedtrials[J]. Oncotarget, 2017, 8(42):73009-73016.
[11]	Chen YX, Yang Q, Kuang JJ, et al. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials[J]. Gastroenterol Res Pract, 2014:594930.
[12]	Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials[J]. The Oncologist, 2013, 18(9):1004-1012.
[13]	Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study[J]. The Oncologist, 2009, 14(9):862-870. doi: 10.1634/theoncologist.2009-0071
[14]	Yu ZQ, Huang R, Zhao L, et al. Safety profifile of oxaliplatin in 3, 687 patients with cancer inchina: apost-marketing surveillance study[J]. Front Oncol, 2021, 21(11):757196.
[15]	Boku N, Sugihara K, Kitagawa Y, et al. Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients[J]. Jpn J Clin Oncol, 2014, 44(3):214-223. doi: 10.1093/jjco/hyt196
[16]	Yoshino T, Uetake H, Funato Y, et al. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer[J]. Jpn J Clin Oncol, 2021, 51(5):700-706. doi: 10.1093/jjco/hyaa243
[17]	秦叔逵,邓艳红,毕锋.贝伐珠单抗联合含氟尿嘧啶类化疗方案治疗晚期转移性结直肠癌的前瞻性、非干预性、全国多中心临床研究(REACT)[J].临床肿瘤学杂志,2016,21(10):865-873.
[18]	Schilsky RL. Finding the evidence in real-world evidence: moving from data to information to knowledge[J]. J Am Coll Surg, 2017, 224(1):1-7. doi: 10.1016/j.jamcollsurg.2016.10.025
[19]	Michel D, Lone NP, Leopold O, et al. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study[J]. EurJ Cancer, 2019, 123:146-154. doi: 10.1016/j.ejca.2019.09.015
[20]	Montes AF, Lopez CL, Martinez GA, et al. Prognostic nomogram and patterns of use of FOLFIRI-Aflibercept in advanced colorectal cancer: a real-world data analysis[J]. The Oncologist, 2019, 24(8):687-695.
[21]	Qi L, Peng L, Dakui L, et al. Combination of carcinoembryonic antigen with the American joint committee on cancer TNM staging system in rectal cancer: a real-world and large population-based study[J]. Onco Targets Ther, 2018, 13(11):5827-5834.
[22]	Montes AF, Lago NM, Rúaet MC, et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers[J]. Cancer Med, 2019, 8(3):882-889.
[23]	Noepel DS, Juettenull H, Feder IS, et al. High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early colon cancer (CC); real world data from the AIO molecular registry colopredict plus[J]. Z Gastroenterol, 2020, 58(6):533-541. doi: 10.1055/a-1156-4433
[24]	Kayhanian H, Goode E, Sclafani F, et al. Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case control study[J]. Clin Colorectal Cancer, 2018, 17(1):69-76. doi: 10.1016/j.clcc.2017.10.006
[25]	Kawamura H, Morishima T, Sato A, et al. Effect of adjuvant chemotherapy on survival benefit in stage Ⅲ colon cancer patients stratified by age: a Japanese realworld cohort study[J]. BMC Cancer, 2020, 20(1):19. doi: 10.1186/s12885-019-6508-1
[26]	Laurent M, Guetz G, Garin BS, et al. Chronological age and risk of chemotherapy nonfeasibility: a real-life cohort study of 153 stage Ⅱ or Ⅲ colorectal cancer patients given adjuvant- modified FOLFOX6[J]. Am J Clin Oncol, 2018, 41(1):73-80. doi: 10.1097/COC.0000000000000233
[27]	Toshiki M, Hiroya T, Satoshi H. Regorafenib versus Trifluridine/Tipiracil for refractory metastatic colorectal cancer: a retrospective comparison[J]. Clin Colorectal Cancer, 2017, 16(2):15-22.
[28]	Shen L, Li Q, Wang W, et al. Treatment patterns and direct medical costs of metastatic colorectal cancer patients: A retrospective study of electronic medical records from urban China[J]. J Med Econ, 2020, 23(5):456-463. doi: 10.1080/13696998.2020.1717500
[29]	周昌明,郭天安,莫淼,等.以大型单中心医院登记为基础的1.37万例结直肠癌手术患者生存报告[J].中国癌症杂志,2020,30(4):246-253.